|
Case | Age | Symptoms | Hematological diagnosis | Time from systemic disease to MS | Treatment | Outcomes |
|
7 [13] | 61 | Hematuria and frequency | AML | Diagnosed simultaneously | Doxorubicin, vincristine, cytarabine, and prednisone | Died 5.5 months after MS diagnosis |
8 [14] | 65 | Urinary retention and weight loss | AML-M4 (FAB classification) | Diagnosed simultaneously | Chemotherapy (unspecified) | Died 3 weeks after MS diagnosis |
9 [15] | 72 | Urinary retention | CMML | Diagnosed simultaneously | Etoposide | CMML progressed to AML at 3 months and then died at 4 months after MS diagnosis |
10 [16] | N/A | Urinary retention | AML | Diagnosed simultaneously | Chemotherapy (unspecified) | Died; no details |
11 [17] | 8 | Urinary retention | AML-M2 (FAB classification) | Diagnosed simultaneously | High-dose cytarabine | N/A |
12 [18] | 44 | Lower urinary tract symptoms | AML | Diagnosed simultaneously | Chemotherapy and SCT | CR and further follow-up N/A |
13 [13] | 72 | Urinary retention and testicular pain | MDS | 11 months | RT to the prostate bed for hematuria | N/A |
14 [19] | 65 | Asymptomatic, indurated PSA | AML-M5 (FAB classification) | 13 months | RT and then salvage chemotherapy | Initially treated with RT, developed AML relapse at 2 months, and underwent salvage chemotherapy. Alive at 5 months after MS diagnosis |
15 [20] | 68 | Urinary retention | AML-M2 (FAB classification) | 9 years | RT and chemotherapy (unspecified) | Progressed to AML at 6 months after MS diagnosis and died during salvage chemotherapy shortly after |
16 [6] | 66 | Asymptomatic, rising PSA | MDS status after SCT | 6 months | Induction chemotherapy and donor lymphocyte infusion | CR and alive at 1 year after MS diagnosis |
|